A Phase 2b open-label, single-arm study to evaluate pharmacokinetics, efficacy, safety and tolerability of letermovir in pediatric participants from birth to less than 18 years of age at risk of developing CMV infection and/or disease following HSCT

Administered By

Awarded By

Contributors

Start/End

  • October 10, 2018 - October 31, 2021